Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 19/20 | 1.00 |
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 0.77 |
| ▸ | FLT4 | P35916 | 12/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.75 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.75 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7455267 | 0.99 | FLT1 (0.98) | FLT1KDRFGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7455695 | 0.95 | FLT1 (0.91) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL17520360 | 0.91 | KDR (0.83) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL19220788 | 0.91 | KDR (0.83) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL7453490 | 0.90 | FLT1 (0.81) | FLT1KDRFGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7456068 | 0.89 | FLT1 (0.80) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL11156 | 0.87 | EGFR (1.00) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL7456200 | 0.87 | FLT1 (0.77) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL17520362 | 0.87 | EGFR (1.00) | FLT1KDRFGFR1EGFRFLT4 | |
| SCHEMBL7451363 | 0.87 | KDR (0.77) | FLT1KDRFGFR1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | claimed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | claimed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | FLT1 1/4885KDR 3/4885FGFR1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.